SCHEMBL12698403

SCHEMBL12698403

C=C/C=C(\C=C/C)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14922420 0.83
SCHEMBL25038788 0.82
SCHEMBL14240725 0.82
SCHEMBL13786730 0.81 ALDH1A1 (0.33)
SCHEMBL8344137 0.79
SCHEMBL14865200 0.79 ALDH1A1 (0.32)
SCHEMBL18413403 0.79
SCHEMBL7058950 0.78 TSHR (0.45)
SCHEMBL18389724 0.78 LMNA (0.30)
SCHEMBL12214390 0.78 GRIK1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11637256-B2 Quantum dots with charge-transporting ligands NANOSYS, INC. (US) 2023-04-25 US disclosed
US-10875834-B2 Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives VIRGINIA COMMONWEALTH UNIVERSITY (US) 2020-12-29 US disclosed
US-10804467-B2 Method of manufacturing organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2020-10-13 US disclosed
US-20200067006-A1 QUANTUM DOTS WITH CHARGE-TRANSPORTING LIGANDS NANOSYS, INC. (US) 2020-02-27 US disclosed
WO-2020040982-A1 QUANTUM DOTS WITH CHARGE-TRANSPORTING LIGANDS NANOSYS, INC. (US) 2020-02-27 WO disclosed
US-20190256483-A1 PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-08-22 US disclosed
US-20180130949-A1 METHOD OF MANUFACTURING ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2018-05-10 US disclosed
WO-2017201532-A1 METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS BIOMED VALLEY DISCOVERIES, INC. (US) 2017-11-23 WO disclosed
US-20160317517-A1 CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS BIOMED VALLEY DISCOVERIES, INC. 2016-11-03 US disclosed
WO-2016123581-A1 CRYSTALLINE C21H22C12N4O2 MALONATE BIOMED VALLEY DISCOVERIES, INC. (US) 2016-08-04 WO disclosed
WO-2015095842-A2 METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS BIOMED VALLEY DISCOVERIES, INC. (US) 2015-06-25 WO disclosed
WO-2014160967-A9 C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS BIOMED VALLEY DISCOVERIES, INC. (US) 2014-12-24 WO disclosed
WO-2014160950-A1 C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS BIOMED VALLEY DISCOVERIES, INC. (US) 2014-10-02 WO disclosed
WO-2014160967-A2 C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS BIOMED VALLEY DISCOVERIES, INC. (US) 2014-10-02 WO disclosed
US-8709299-B2 Dye sensitised solar cell BASF SE (DE) 2014-04-29 US disclosed
US-20130112106-A1 ENVIRONMENTALLY FRIENDLY CORROSION INHIBITOR APERGY ESP SYSTEMS, LLC 2013-05-09 US disclosed
WO-2012170371-A1 COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS N30 PHARMACEUTICALS, LLC (US) 2012-12-13 WO disclosed
WO-2012089127-A1 CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) 2012-07-05 WO disclosed
US-7531669-B2 Methods for treating neural disorders and conditions, and compounds useful therefor THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2009-05-12 US disclosed
WO-2008043846-A2 NEW ISOCARBOSTYRIL ALKALOID DERIVATIVES HAVING ANTI-PROLIFERATIVE AND ANTI-MIGRATORY ACTIVITIES UNIBIOSCREEN SA (BE) 2008-04-17 WO disclosed